VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
DAREDaré Bioscience, Inc.
$2.17$32M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksDAREEarnings History

DARE logoDaré Bioscience, Inc. (DARE) Earnings History

Net Loss

15 years of earnings data (2011–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$12M
● Net Loss
TTM EPS (Diluted)
$-0.83
Per share, diluted
YoY EPS Growth
-150.0%
Declining
Net Margin
-1300.7%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-1315.5%
Gross Margin-137.5%
Return on Equity-471.4%
Return on Assets-49.1%
Record Annual Net Income-$4MFY2024
Record Quarterly EPS$1.52Q2 2024
Consecutive Profitable Years0years
Q1 2026
Net Income-$3M
EPS (Diluted)$-0.21
YoY Growth-150.0%Declining
QoQ Growth-108.1%Declining

Loading earnings history...

Daré Bioscience, Inc. (DARE) Earnings Overview

As of June 22, 2026, Daré Bioscience, Inc. (DARE) reported trailing twelve-month net income of -$12M, reflecting -150.0% year-over-year growth. The company earned $-0.83 per diluted share over the past four quarters, with a net profit margin of -1300.7%.

Looking at the long-term picture, DARE's historical earnings data spans multiple years. The company achieved its highest annual net income of -$4M in fiscal 2024.

Daré Bioscience, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including TPVG (-$12M net income, 50.6% margin), EVAX (-$8M net income, -102.4% margin), CODA ($5M net income, 15.5% margin), DARE has room to improve margins relative to the peer group. Compare DARE vs TPVG →

DARE Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
DARE logoDARECurrent
-$12M$-0.83-1300.7%-471.4%-150.0%—
TPVG logoTPVG
-$12M$-0.1050.6%14.1%+48.8%
EVAX logoEVAX
-$8M$-1.20-102.4%-100.2%+87.7%
CODA logoCODA
$5M$0.4415.5%7.4%+15.6%
ANIP logoANIP
$90M$4.168.9%16.2%+419.2%
CRVS logoCRVS
-$44M$-0.49--32.6%+48.0%
Best in group
Lowest in group

DARE Historical Earnings Data (2011–2025)

15 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$13M-230.6%-$14M$-1.20-1300.7%-1315.5%
2024-$4M+86.6%-$23M$-0.48-41430.9%-239692.2%
2023-$30M+2.5%-$31M$-4.15-1074.2%-1101.9%
2022-$31M+20.0%-$31M$-4.39-309.5%-313.9%
2021-$39M-41.2%-$39M$-7.52--
2020-$27M-92.1%-$27M$-10.93--
2019-$14M+14.8%-$14M$-10.99--
2018-$17M-45.5%-$17M$-30.16--
2017-$12M+70.7%-$11M$-3.56--
2016-$39M+0.7%-$37M$-30.02-5131.2%-4850.4%
2015-$40M-69.6%-$37M$-15.57--
2014-$23M-36.2%-$20M$-192.00-29177.5%-25348.8%
2013-$17M+22.4%-$16M$-108.19-285716.7%-264333.3%
2012-$22M-13.0%-$22M$-280.83-3536.2%-3452.0%
2011-$20M--$19M$-267.41-6414.1%-6189.5%

Download Data

Export DARE earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

15+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

DARE — Frequently Asked Questions

Quick answers to the most common questions about buying DARE stock.

What is DARE earnings per share (EPS)?

DARE trailing twelve-month (TTM) diluted EPS is $-0.83, reflecting -150.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2011 to 2025 is available in the table on this page.

What is Daré Bioscience, Inc.'s net income?

Daré Bioscience, Inc. (DARE) trailing twelve-month net income is $-12M as of 2025. Earnings declined -150.0% year-over-year.

Is DARE profitable?

DARE is not currently profitable on a TTM basis, reporting a net loss of $-12M. Net margin is -1300.7%. Investors should monitor for a return to profitability.

What is DARE's earnings growth rate?

DARE compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2011 to 2025.

What are DARE's profit margins?

Daré Bioscience, Inc. net profit margin is -1300.7%, operating margin is -1315.5%, and gross margin is -137.5%. Below-average margins reflect competitive or cost pressures. Return on Equity is -471.4%.

Is DARE growing earnings?

DARE earnings are declining — EPS fell -150.0% year-over-year. TTM net income dropped to $-12M. This contrasts with the 5-year CAGR of N/A.

What was DARE's best earnings year?

Daré Bioscience, Inc.'s highest annual net income on record is $-4M, achieved in fiscal year 2024. Earnings history on this page spans 2011 to 2025 and includes all annual and quarterly figures.

What were DARE's earnings last quarter?

DARE's most recent reported quarter was Q1 2026. Net income was $-3M with diluted EPS of $-0.21. For a full breakdown of all quarters, see the quarterly earnings table on this page.

DARE Earnings Over Time (2011–2025)

Net income & EPS — annual and quarterly view